首页 | 本学科首页   官方微博 | 高级检索  
     

吲哚美辛栓与奥曲肽预防内镜下逆行胰胆管造影术术后胰腺炎临床评价
引用本文:刘少波,苏剑东,江堤,刘美红,廖素环. 吲哚美辛栓与奥曲肽预防内镜下逆行胰胆管造影术术后胰腺炎临床评价[J]. 中国药业, 2020, 0(9): 151-153
作者姓名:刘少波  苏剑东  江堤  刘美红  廖素环
作者单位:广东省东莞东华医院
基金项目:2017年广东省东莞市社会科技发展(一般)项目[201750715046012]。
摘    要:目的探讨奥曲肽与吲哚美辛栓对内镜下逆行胰胆管造影术(ERCP)后胰腺炎的预防作用。方法选取医院2016年3月至2019年2月收治的行ERCP患者180例,随机分为对照组、奥曲肽组、吲哚美辛组,各60例。监测3组患者ERCP术后2~4 h、24 h血清淀粉酶水平及术后胰腺炎、高淀粉酶血症、不良反应、住院总费用、住院日。结果奥曲肽组、吲哚美辛组术后2~4 h血清淀粉酶水平、术后胰腺炎和高淀粉酶血症的发生率、平均住院总费用、平均住院日均低于对照组(P<0.05),吲哚美辛组术后24 h血清淀粉酶水平低于对照组(P<0.05),但奥曲肽组术后24 h血清淀粉酶水平与对照组比较无显著差异(P>0.05)。结论吲哚美辛栓与奥曲肽注射液均可用于预防ERCP术后胰腺炎和术后高淀粉酶血症,可降低患者的住院费用,缩短住院时间。

关 键 词:吲哚美辛栓  奥曲肽  内镜下逆行胰胆管造影  胰腺炎  高淀粉酶血症

Indomethacin Suppository and Octreotide for Preventing Pancreatitis After ERCP
LIU Shaobo,SU Jiandong,JIANG Di,LIU Meihong,LIAO Suhuan. Indomethacin Suppository and Octreotide for Preventing Pancreatitis After ERCP[J]. China Pharmaceuticals, 2020, 0(9): 151-153
Authors:LIU Shaobo  SU Jiandong  JIANG Di  LIU Meihong  LIAO Suhuan
Affiliation:(Dongguan Donghua Hospital,Dongguan,Guangdong,China 523110)
Abstract:Objective To investigate the preventive effect of octreotide and indomethacin suppository on pancreatitis after endoscopic retrograde cholangiopancreatography(ERCP).Methods A total of 180 patients who were treated with ERCP from March 2016 to February 2019 were selected and randomly divided into the control group,the octreotide group and the indomethacin group,60 cases in each group.The serum amylase levels at 2-4 h and 24 h after ERCP,post-ERCP pancreatitis,hyperamylasemia,adverse reactions,t otal hospitalization cost,hospitalization day were monitored.Results The levels of serum amylase at 2-4 h after ERCP,the incidence of post-ERCP pancreatitis and hyperamylasemia,average total hospitalization cost and average hospitalization day in the octreotide group and the indomethacin group were significantly lower than those in the control group(P<0.05).The levels of serum amylase at postoperative 24 h in the indomethacin group was significantly lower than this in the control group(P<0.05),but there was no statistical difference between the octreotide group and the control group(P>0.05).Conclusion Indomethacin suppository and octreotide injection can be used to prevent pancreatitis and hyperamylasemia after ERCP,and reduce hospitalization costs and hospitalization day.
Keywords:indomethacin suppository  octreotide  endoscopic retrograde cholangiopancreatography  pancreatitis  hyperamylasemia
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号